Darren Murphy, Chairman
Jon Hudson, Director
Conal Timoney, Associate
Conal analyses the impact of Brexit for the MedTech and Pharma sector, focussing on the complex and multi-national supply chains that will be disrupted by any exit from the European Single Market and/or Customs Union. This includes establishing the true cost of exit to MedTech and Pharma companies who manufacture in the UK for sale in Europe, companies that manufacture in the EU and export to the UK, and most commonly, those who have an integrated supply chains where manufacturing is split, with components originating in multiple countries and which have built their production over time on the expectation that open borders will not be disrupted. He has provided analysis on how to understand likely costs of tariffs, country or origin rules and other non-tariff impacts (including customs posts, currency fluctuations and possible divergent regulatory environments) as well as plans for companies to have their voice heard before final decisions are made, whether in the UK, Brussels or other EU states.
Conal’s background includes several years working for the UK Department of Health and NHS bodies, as well as MedTech and other healthcare providers, including Public Policy roles that involved engaging in London and Brussels. A graduate of Trinity College Dublin, Conal previously spent a decade in the US working in health policy at the University of Virginia and politics in Washington, DC.